Inmune Bio, Inc. (INMB) SEC Filing 8-K Material Event for the period ending Tuesday, May 5, 2020

Inmune Bio, Inc.

CIK: 1711754 Ticker: INMB

View differences made from one to another to evaluate Inmune Bio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inmune Bio, Inc..


Assess how Inmune Bio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inmune Bio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Inmune Bio, Inc. provided additional information to their SEC Filing as exhibits

Ticker: INMB
CIK: 1711754
Form Type: 8-K Corporate News
Accession Number: 0001213900-20-010962
Submitted to the SEC: Tue May 05 2020 9:01:15 AM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, May 5, 2020
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: